[go: up one dir, main page]

IN2012DN06581A - - Google Patents

Download PDF

Info

Publication number
IN2012DN06581A
IN2012DN06581A IN6581DEN2012A IN2012DN06581A IN 2012DN06581 A IN2012DN06581 A IN 2012DN06581A IN 6581DEN2012 A IN6581DEN2012 A IN 6581DEN2012A IN 2012DN06581 A IN2012DN06581 A IN 2012DN06581A
Authority
IN
India
Prior art keywords
compositions
active ingredients
carriers
eye
useful
Prior art date
Application number
Inventor
Bastian Theisinger
Sonja Theisinger
Bernhard Günther
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Publication of IN2012DN06581A publication Critical patent/IN2012DN06581A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention provides novel pharmaceutical compositions for the treatment of increased intraocular pressure based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water soluble prostaglandin analogues. The compositions can be administered topically into the eye. The invention further provides kits comprising such compositions.
IN6581DEN2012 2010-03-17 2011-03-16 IN2012DN06581A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10002800 2010-03-17
PCT/EP2011/053949 WO2011113855A2 (en) 2010-03-17 2011-03-16 Pharmaceutical composition for treatment of increased intraocular pressure

Publications (1)

Publication Number Publication Date
IN2012DN06581A true IN2012DN06581A (en) 2015-10-23

Family

ID=42223897

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6581DEN2012 IN2012DN06581A (en) 2010-03-17 2011-03-16

Country Status (15)

Country Link
US (4) US10045996B2 (en)
EP (1) EP2547323B1 (en)
JP (1) JP5816636B2 (en)
KR (1) KR101656121B1 (en)
CN (1) CN102869345B (en)
AU (1) AU2011229235B2 (en)
BR (1) BR112012023421B1 (en)
CA (1) CA2788060C (en)
DK (1) DK2547323T3 (en)
ES (1) ES2564502T3 (en)
HK (1) HK1175398A1 (en)
IN (1) IN2012DN06581A (en)
MX (1) MX2012010684A (en)
PL (1) PL2547323T3 (en)
WO (1) WO2011113855A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2547323B1 (en) 2010-03-17 2016-01-27 Novaliq GmbH Pharmaceutical composition for treatment of increased intraocular pressure
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
PT2714010T (en) 2011-05-25 2017-05-05 Novaliq Gmbh Topical pharmaceutical composition based on semifluorinated alkanes
JP6084987B2 (en) 2012-01-23 2017-02-22 ノバリック ゲーエムベーハー Stabilized protein composition based on semifluorinated alkanes
EP2664329A1 (en) * 2012-05-15 2013-11-20 F. Holzer GmbH Ophthalmological vehicle system
EP2858628A1 (en) 2012-06-25 2015-04-15 Bayer HealthCare LLC Topical ophthalmological pharmaceutical composition containing sunitinib
DE202013012742U1 (en) 2012-09-12 2019-01-22 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
ES2682064T3 (en) * 2012-09-12 2018-09-18 Novaliq Gmbh Eye wash compositions
EP3488847B1 (en) 2012-09-12 2023-11-08 Novaliq GmbH Semifluorinated alkane compositions
EP2783703A1 (en) * 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
ES2687094T3 (en) 2013-07-23 2018-10-23 Novaliq Gmbh Stabilized antibody compositions
AU2015227307A1 (en) 2014-03-03 2016-10-13 Encore Vision, Inc. Lipoic acid choline ester compositions and methods of use
CN104606173A (en) * 2014-12-26 2015-05-13 上海杰视医疗科技有限公司 Application of fluorine-contained alkane
PT3356313T (en) 2015-09-30 2020-07-13 Novaliq Gmbh Semifluorinated compounds for ophthalmic administration
PT3355990T (en) 2015-09-30 2019-09-11 Novaliq Gmbh Semifluorinated compounds and their compositions
PL3442480T3 (en) 2016-06-23 2020-04-30 Novaliq Gmbh Topical administration method
US11478437B2 (en) 2016-07-05 2022-10-25 Jenivision Inc. Formulations for hair growth
CA3036297C (en) 2016-09-22 2023-09-05 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
WO2018055101A1 (en) 2016-09-23 2018-03-29 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
KR102602890B1 (en) * 2016-12-22 2023-11-15 노바리크 게엠베하 Composition containing tacrolimus for treatment of intraocular inflammatory eye diseases
ES2957559T3 (en) 2017-04-21 2024-01-22 Dermaliq Therapeutics Inc Iodine compositions
EP3619186B1 (en) 2017-05-05 2021-02-17 Novaliq GmbH Process for the production of semifluorinated alkanes
WO2018206656A1 (en) 2017-05-12 2018-11-15 Novaliq Gmbh Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
KR20200037230A (en) * 2017-06-30 2020-04-08 제니비젼 인크. Formulations for hair growth
IL273531B2 (en) * 2017-09-27 2024-05-01 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
CN111182893A (en) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 Ophthalmic composition comprising F6H8
MX2020009132A (en) 2018-03-02 2020-12-11 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol.
JP2021522219A (en) * 2018-04-27 2021-08-30 ノバリック ゲーエムベーハー Ophthalmic composition containing tafluprost for the treatment of glaucoma
AU2019263302C1 (en) * 2018-05-01 2024-10-31 Chibi, Inc. Liquid depot for non-invasive sustained delivery of agents to the eye
BR112021005350A8 (en) 2018-09-27 2023-03-21 Novaliq Gmbh LIPID BARRIER REPAIR
CA3112031A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
JP2022543402A (en) * 2019-08-09 2022-10-12 ノバリック ゲーエムベーハー Topical compositions containing prostaglandin analogues
CN115867264A (en) * 2020-06-01 2023-03-28 Ads医疗有限责任公司 Topical ophthalmic compositions and methods for treating abnormal angiogenesis

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2616927A (en) 1950-05-12 1952-11-04 Minnesota Mining & Mfg Fluorocarbon tertiary amines
US4452818A (en) * 1982-03-19 1984-06-05 Haidt Sterling J Extraocular method of treating the eye with liquid perfluorocarbons
US5077036A (en) 1986-01-14 1991-12-31 Alliance Pharmaceutical Corp. Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid
JPS6452722A (en) 1987-05-01 1989-02-28 Anjierini Pharmaceut Inc Ophthalmic composition
JP3046346B2 (en) 1990-03-12 2000-05-29 昭和電工株式会社 External preparation base or auxiliary agent and human or animal external preparation containing it
US5518731A (en) 1990-09-27 1996-05-21 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
US6458376B1 (en) 1990-09-27 2002-10-01 Allergan, Inc. Nonaqueous fluorinated drug delivery suspensions
US5152997A (en) 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
US5326566A (en) 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
GB9114374D0 (en) 1991-07-03 1991-08-21 Smithkline Beecham Plc Novel process
FR2679150A1 (en) 1991-07-17 1993-01-22 Atta PREPARATIONS CONSISTING OF A FLUOROCARBIDE OR HIGHLY FLUORINE COMPOUND AND A LIPOPHILIC-FLUOROPHILIC ORGANIC COMPOUND, AND THEIR USES.
US6602900B2 (en) 1992-09-21 2003-08-05 Allergan, Inc. Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5336175A (en) 1992-10-29 1994-08-09 Mames Robert N Method for the treatment of retinal detachments
US6184250B1 (en) * 1993-08-03 2001-02-06 Alcon Laboratories, Inc. Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
US5370313A (en) 1994-01-10 1994-12-06 Beard; Walter C. Sterile liquid dispenser
DE4405627A1 (en) 1994-02-22 1995-08-24 Hoechst Ag Oil emulsions containing fluorocarbons
FR2720943B1 (en) 1994-06-09 1996-08-23 Applic Transferts Technolo Stable inverse emulsions with a high concentration of fluorinated compound (s) and their use for the pulmonary administration of medicaments and for the manufacture of multiple emulsions.
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US5696164A (en) 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
DE19536504C2 (en) 1995-09-29 1999-09-23 H Meinert Use of fluorinated alkanes
US5874469A (en) * 1996-01-05 1999-02-23 Alcon Laboratories, Inc. Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
FR2752161B1 (en) 1996-08-07 1998-09-25 Atta MULTIPLE HYDROCARBON-IN-WATER-IN-FLUOROCARBON EMULSIONS FOR THE TRANSPORT OF HYDROPHILIC AND / OR LIPOPHILIC DRUG SUBSTANCES
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
IN184589B (en) 1996-10-16 2000-09-09 Alza Corp
DE19709704C2 (en) 1997-03-10 1999-11-04 Michael Georgieff Use of a liquid preparation of xenon for intravenous administration when inducing and / or maintaining anesthesia
US5980936A (en) 1997-08-07 1999-11-09 Alliance Pharmaceutical Corp. Multiple emulsions comprising a hydrophobic continuous phase
US6645963B2 (en) 1997-11-05 2003-11-11 Senju Pharmaceutical Co., Ltd. Prolonged-action eye drop
US5851544A (en) 1997-12-18 1998-12-22 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic skin or hair care compositions containing fluorocarbons infused with carbon dioxide
US5981607A (en) 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
JP2001523273A (en) 1998-02-09 2001-11-20 マクロケム・コーポレーシヨン Antifungal nail lacquer and method of using same
DE19861012A1 (en) 1998-03-18 1999-09-30 Pharm Pur Gmbh Ophthalmological use of fluorocarbon with low dissolved oxygen content, e.g. for treating ischemic retinal disease
WO2000010531A1 (en) 1998-08-19 2000-03-02 Rtp Pharma Inc. Injectable aqueous dispersions of propofol
US6140374A (en) 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6159977A (en) 1998-11-16 2000-12-12 Astan, Inc. Therapeutic anti-fungal nail preparation
EP1152749B1 (en) 1999-02-08 2006-04-12 ALZA Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
AU3898700A (en) 1999-03-15 2000-10-04 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
US6177477B1 (en) 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
DE19926890C1 (en) * 1999-06-12 2000-07-27 Pharm Pur Gmbh Use of highly fluorinated oligomeric alkanes in ophthalmology, especially as vitreous humor substitutes, retinal tamponade materials, liquid implants, tear fluid substitutes and drug carriers
DE19938668B4 (en) 1999-08-14 2006-01-26 Bausch & Lomb Inc. Artificial tears
US6528086B2 (en) 1999-09-28 2003-03-04 Zars, Inc. Methods and apparatus for drug delivery involving phase changing formulations
JP2001158734A (en) 1999-12-02 2001-06-12 Lion Corp Composition for ophthalmology and method for inhibiting adsorption to soft contact lens
US20030018044A1 (en) 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
DE10024413A1 (en) 2000-05-19 2001-12-06 Mika Pharma Gmbh Pharmaceutical and / or cosmetic preparation
DE10042412B4 (en) 2000-08-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag Transceiver for bus subscriber of bus system of building system engineering, has two wires, where microcontroller is connected with receiver unit over connection on one hand, which is connected to two wires of bus system
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
US20030027833A1 (en) 2001-05-07 2003-02-06 Cleary Gary W. Compositions and delivery systems for administration of a local anesthetic agent
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
RU2302857C2 (en) 2001-09-04 2007-07-20 Тромсдорф ГмбХ унд Ко.КГ Арцнаймиттель Method and plaster for preventing and/or treating the cases of finger-nail dysfunction and/or growth disorders
AU2002325220A1 (en) 2002-05-24 2003-12-12 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Drop-forming ophthalmic gel preparation comprising diclofenamide and timolol
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
MXPA06002163A (en) 2003-08-25 2006-05-22 Foamix Ltd Penetrating pharmaceutical foam.
US20050079210A1 (en) 2003-10-09 2005-04-14 Gupta Shyam K. Liposomal delivery system for topical pharmaceutical, cosmeceutical, and cosmetic ingredients
MXPA06003316A (en) 2003-10-10 2006-06-08 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues.
WO2005051305A2 (en) 2003-11-19 2005-06-09 Barnes-Jewish Hospital Enhanced drug delivery
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
WO2005099718A1 (en) 2004-04-19 2005-10-27 Centre National De La Recherche Scientifique (C.N.R.S.) Lung surfactant supplements
WO2005123035A1 (en) 2004-06-08 2005-12-29 Ocularis Pharma, Inc. Hydrophobic ophthalmic compositions and methods of use
US7063241B2 (en) 2004-06-10 2006-06-20 Allergan, Inc. Dispensing tip
US20060009522A1 (en) 2004-07-01 2006-01-12 Reza Dana Compositions and methods for treating eye disorders and conditions
US20060078580A1 (en) 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US7740875B2 (en) 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
EP1688161A1 (en) 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
GB0511499D0 (en) 2005-06-06 2005-07-13 Medpharm Ltd Topical ungual formulations
MX2008001746A (en) 2005-08-05 2008-04-07 Bharat Serums & Vaccines Ltd Intravenous propofol emulsion compositions having preservative efficacy.
FR2892023B1 (en) 2005-10-14 2009-09-25 Galderma Sa PHARMACEUTICAL COMPOSITION BASED ON AMOROLFIN AND WATER-SOLUBLE FILMOGENIC AGENT FOR UNIGEAL AND PERI-UNGUEAL APPLICATION
DE102005050431A1 (en) 2005-10-21 2007-04-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for the administration of lipophilic and / or less skin-permeable active ingredients
DE102005055811A1 (en) 2005-11-23 2007-05-31 Novaliq Gmbh Using composition containing semifluorinated alkane and/or siloxane for preservation or organs and limbs, ensures proper provision of oxygen
TWI376239B (en) 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
US20070238732A1 (en) 2006-04-10 2007-10-11 Allergan, Inc. Brimonidine and timolol compositions
KR20090053892A (en) 2006-07-25 2009-05-28 오스모티카 코프. eye drops
EP2046290A4 (en) 2006-08-04 2011-08-17 Insys Therapeutics Inc Aqueous dronabinol formulations
JP5694664B2 (en) 2006-09-29 2015-04-01 サーモディクス，インコーポレイティド Biodegradable ocular implant and method for treating ocular diseases
JP5569899B2 (en) 2006-11-28 2014-08-13 ウィスコンシン・アラムナイ・リサーチ・ファウンデーション Fluoropolymer-based emulsion for intravenous delivery of volatile fluorinated anesthetics
KR20090087917A (en) 2006-12-07 2009-08-18 썬 파마 어드밴스트 리서치 컴패니 리미티드 Metered drop bottles for dispensing microliters of liquid in the form of drops
CN200977281Y (en) 2006-12-08 2007-11-21 陈宇 Dropping bottle with dropping-aiding device
ITMI20070890A1 (en) 2007-05-04 2008-11-05 Sifi Spa OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA
US8492334B2 (en) 2007-06-21 2013-07-23 Yale University Sustained intraocular delivery of drugs from biodegradable polymeric microparticles
FR2918891B1 (en) 2007-07-20 2009-09-25 Thea Sa Lab OPHTHALMIC SOLUTION BASED ON PROSTAGLANDINS WITHOUT PRESERVATIVE
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
DE102007055046A1 (en) 2007-11-19 2009-05-28 Fluoron Gmbh infusion
US20090136430A1 (en) 2007-11-27 2009-05-28 Dugger Harry A Antihistamine/Corticosteroid preparations for the treatment of atopic dermatitis
ES2377152T3 (en) 2008-04-18 2012-03-22 Novaliq Gmbh Inhalative and instillative use of semi-fluorinated alkanes as vehicles of active ingredients in the intrapulmonary region
US20100006600A1 (en) 2008-07-14 2010-01-14 Dascanio Gustavo A Fluid dispenser including hydrophobic ring
HUE032158T2 (en) 2008-10-31 2017-09-28 Univ Mississippi Process of preparation of delta-9-thc-amino acid esters
CA2743824A1 (en) 2008-11-26 2010-06-03 Surmodics, Inc. Implantable ocular drug delivery device and methods
US8501800B2 (en) 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
IT1393419B1 (en) 2009-03-19 2012-04-20 Medivis S R L OPHTHALMIC COMPOSITIONS OF OMEGA-3 AND OMEGA-6 POLYSATURATED FATTY ACIDS.
WO2010146536A1 (en) 2009-06-18 2010-12-23 Koninklijke Philips Electronics N.V. Suspension of particles with drug
JP5736635B2 (en) 2009-06-25 2015-06-17 ライオン株式会社 Dry eye treatment
KR101702157B1 (en) 2009-06-25 2017-02-13 라이온 가부시키가이샤 Ophthalmic composition
ES2622097T3 (en) 2009-07-24 2017-07-05 Mika Pharma Gesellschaft Für Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh Procedure for the development of a liquid composition to be applied as a foam on the skin as well as a composition that can be applied topically
JP2011024841A (en) 2009-07-28 2011-02-10 健太 ▲浜崎▼ Instillation aid
EP2332525A1 (en) 2009-11-23 2011-06-15 Novaliq GmbH Pharmaceutical composition comprising propofol
EP2335735A1 (en) 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
EP2547323B1 (en) 2010-03-17 2016-01-27 Novaliq GmbH Pharmaceutical composition for treatment of increased intraocular pressure
DE102010022567A1 (en) 2010-06-02 2011-12-08 Fluoron Gmbh preparation
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
BR112013016661B1 (en) 2011-01-04 2021-08-03 Novaliq Gmbh O/A EMULSIONS COMPRISING SEMI-FLUORINATED ALKANS
PT2714010T (en) 2011-05-25 2017-05-05 Novaliq Gmbh Topical pharmaceutical composition based on semifluorinated alkanes
CN103561724B (en) 2011-05-25 2016-06-29 诺瓦利克有限责任公司 It is administered to the pharmaceutical composition of first
CN202136470U (en) 2011-06-08 2012-02-08 天津市金亿达药用包装材料有限公司 Eye medicine bottle convenient to drip medicine
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
JP6084987B2 (en) 2012-01-23 2017-02-22 ノバリック ゲーエムベーハー Stabilized protein composition based on semifluorinated alkanes
US9549966B2 (en) 2012-02-21 2017-01-24 Massachusetts Eye & Ear Infirmary Inflammatory eye disorders
US9878000B2 (en) 2012-06-20 2018-01-30 University Of Waterloo Mucoadhesive nanoparticle composition comprising immunosuppresant and methods of use thereof
EP3488847B1 (en) * 2012-09-12 2023-11-08 Novaliq GmbH Semifluorinated alkane compositions
DE202013012742U1 (en) 2012-09-12 2019-01-22 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
MX2015007931A (en) 2012-12-18 2015-10-05 Novartis Ag Compositions and methods that utilize a peptide tag that binds to hyaluronan.
EP2783703A1 (en) 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
ES2687094T3 (en) 2013-07-23 2018-10-23 Novaliq Gmbh Stabilized antibody compositions
AU2014332488B2 (en) 2013-10-09 2017-03-09 Johnson Living Trust Dated October 26, 2001, Leonidas A. Johnson, Trustee Methods and compositions for treating and preventing signs or symptoms of eye disease
CN203524843U (en) 2013-10-20 2014-04-09 吕相瑜 Self-service eye drop dropping auxiliary support
WO2015074137A1 (en) 2013-11-20 2015-05-28 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain
CA2943255C (en) 2014-03-31 2023-01-24 Amcor Limited Controlled release container
EP2944324A1 (en) 2014-05-13 2015-11-18 LTS LOHMANN Therapie-Systeme AG Use of semifluorinated alkanes in transdermal therapeutic systems
CA2955964C (en) 2014-08-13 2024-05-07 University Of Florida Research Foundation, Inc. Preservative removal from eye drops
WO2016082644A1 (en) 2014-11-26 2016-06-02 The University Of Hong Kong A semifluorinated alkane based cleaner for removing emulsified droplets in the eye to reduce the complications associated with the emulsification of silicone oil
MA41299A (en) 2014-12-30 2017-11-07 Axim Biotechnologies Inc OPHTHALMIC SOLUTIONS FOR THE TREATMENT OF GLAUCOMA AND CONJUNCTIVITIS
WO2016108130A1 (en) 2014-12-30 2016-07-07 Sun Pharmaceutical Industries Limited Topical pharmaceutical compositions comprising nebivolol for the treatment of diabetic wounds
PT3356313T (en) 2015-09-30 2020-07-13 Novaliq Gmbh Semifluorinated compounds for ophthalmic administration
PT3355990T (en) 2015-09-30 2019-09-11 Novaliq Gmbh Semifluorinated compounds and their compositions
KR20190003997A (en) 2016-06-01 2019-01-10 해롤드 리차드 헬스트롬 Treatment of dry eye syndrome using parasympathetic and anti-sympathetic agents
PL3442480T3 (en) 2016-06-23 2020-04-30 Novaliq Gmbh Topical administration method
CA3036297C (en) 2016-09-22 2023-09-05 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
WO2018055101A1 (en) 2016-09-23 2018-03-29 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
CA3036313A1 (en) 2016-09-28 2018-04-05 Novaliq Gmbh Compositions comprising a cannabinoid receptor binding ligand
KR102602890B1 (en) 2016-12-22 2023-11-15 노바리크 게엠베하 Composition containing tacrolimus for treatment of intraocular inflammatory eye diseases
BR112019012791A2 (en) 2016-12-23 2019-12-03 Novaliq Gmbh ophthalmic composition for treating dry eye disease

Also Published As

Publication number Publication date
JP5816636B2 (en) 2015-11-18
US20190240234A1 (en) 2019-08-08
HK1175398A1 (en) 2013-07-05
US20180303849A1 (en) 2018-10-25
CA2788060C (en) 2017-07-11
CN102869345A (en) 2013-01-09
US10045996B2 (en) 2018-08-14
ES2564502T3 (en) 2016-03-23
WO2011113855A3 (en) 2011-11-17
EP2547323A2 (en) 2013-01-23
US20200206241A1 (en) 2020-07-02
US11324757B2 (en) 2022-05-10
BR112012023421A2 (en) 2016-06-07
CN102869345B (en) 2015-02-11
EP2547323B1 (en) 2016-01-27
KR101656121B1 (en) 2016-09-08
MX2012010684A (en) 2012-11-06
AU2011229235B2 (en) 2014-08-14
AU2011229235A1 (en) 2012-09-13
PL2547323T3 (en) 2016-07-29
US10555953B2 (en) 2020-02-11
KR20130016280A (en) 2013-02-14
JP2013522272A (en) 2013-06-13
CA2788060A1 (en) 2011-09-22
WO2011113855A2 (en) 2011-09-22
BR112012023421B1 (en) 2021-09-14
US10525062B2 (en) 2020-01-07
DK2547323T3 (en) 2016-05-02
US20130046014A1 (en) 2013-02-21

Similar Documents

Publication Publication Date Title
IN2012DN06581A (en)
AU2012214029A8 (en) Rorgammat inhibitors
AR081681A1 (en) METHODS AND COMPOSITIONS FOR THE INTRATECAL ADMINISTRATION OF b-GALACTOCEREBROSIDASA
MY183312A (en) Pharmaceutical formulation
MD20150043A2 (en) Inhibitors of histone demethylases
EP4218759A3 (en) Combination therapy
EA201390908A1 (en) DERIVATIVES OF BICYCLO [3.2.1] OCTYLAMIDE AND THEIR APPLICATION
PH12014500987A1 (en) Neprilysin inhibitors
UA109868C2 (en) N -alkyltriazole compounds asr
MX2013001677A (en) Stable formulations of linaclotide.
DOP2013000243A (en) ACETIL-COA CARBOXILASA REPLACED INHIBITORS
UY33694A (en) ? N1 / N2-LACTAMA ACETIL-COA CARBOXYLASE INHIBITORS ?.
TN2012000543A1 (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
PH12016501462A1 (en) Neprilysin inhibitors
PH12016501461A1 (en) 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors
MX2012012941A (en) Novel ophthalmic compositions.
IN2014DN06869A (en)
TN2013000239A1 (en) New form of administration of enkephalinase inhibitor
IN2014DN00090A (en)
MX2013008340A (en) Novel 4-amino-n-hydroxy-benzamides as hdac inhibitors for the treatment of cancer.
EA201490222A1 (en) COMBINED COMPOSITIONS BASED ON DARUNAVIR
EA201490223A1 (en) COMPOSITIONS BASED ON DARUNAVIR
MX2019012375A (en) Lfa-1 inhibitor formulations.
IN2014DN05972A (en)
TN2012000105A1 (en) Spirolactam derivatives and uses of same